Compare Stocks

Date Range: 

 SavaraMinerva NeurosciencesAdamis PharmaceuticalsCorvus PharmaceuticalsMetacrine
SymbolNASDAQ:SVRANASDAQ:NERVNASDAQ:ADMPNASDAQ:CRVSNASDAQ:MTCR
Price Information
Current Price$1.63$2.26$0.75$2.91$3.48
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.91.61.31.81.7
Analysis Score3.53.33.03.33.5
Community Score2.42.83.02.54.0
Dividend Score0.00.00.00.00.0
Ownership Score2.51.70.03.30.8
Earnings & Valuation Score1.30.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$4.67$6.75$1.25$6.75$20.67
% Upside from Price Target186.30% upside198.67% upside67.72% upside131.96% upside493.87% upside
Trade Information
Market Cap$88.41 million$96.55 million$110.97 million$111.48 million$91.21 million
Beta1.181.491.681.81N/A
Average Volume3,451,126541,49015,778,859789,88277,994
Sales & Book Value
Annual RevenueN/AN/A$22.11 millionN/AN/A
Price / SalesN/AN/A5.02N/AN/A
Cashflow$6.27 per shareN/AN/AN/AN/A
Price / Cash0.26N/AN/AN/AN/A
Book Value$2.47 per share$0.71 per share$0.58 per share$2.42 per shareN/A
Price / BookN/AN/A1.29N/AN/A
Profitability
Net Income$-78,170,000.00$-72,180,000.00$-29,310,000.00$-46,670,000.00N/A
EPS$4.57($1.85)($0.55)($1.59)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-188.31%N/AN/A
Return on Equity (ROE)-55.13%-51.19%-99.57%-79.15%N/A
Return on Assets (ROA)-40.08%-29.75%-67.47%-63.99%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.33%N/A0.05%N/A0.09%
Current Ratio12.61%6.49%1.32%4.38%27.04%
Quick Ratio12.61%6.49%1.16%4.38%27.04%
Ownership Information
Institutional Ownership Percentage40.66%66.28%7.36%60.80%52.31%
Insider Ownership Percentage4.77%12.00%5.90%45.12%N/A
Miscellaneous
EmployeesN/A111164235
Shares Outstanding54.24 million42.72 million148.89 million38.31 million26.21 million
Next Earnings DateN/A5/12/2021 (Confirmed)5/17/2021 (Estimated)7/29/2021 (Estimated)6/17/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors - StreetInsider.comCaribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors - StreetInsider.com
streetinsider.com - May 5 at 6:27 PM
Zacks: Analysts Anticipate Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per ShareZacks: Analysts Anticipate Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per Share
americanbankingnews.com - May 5 at 3:52 PM
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors - Yahoo FinanceCaribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors - Yahoo Finance
finance.yahoo.com - May 5 at 8:26 AM
Metacrine, Inc. (NASDAQ:MTCR) Short Interest UpdateMetacrine, Inc. (NASDAQ:MTCR) Short Interest Update
americanbankingnews.com - May 1 at 5:46 AM
News Flash: Analysts Just Made A Sizeable Upgrade To Their Clearfield, Inc. (NASDAQ:CLFD) Forecasts - NasdaqNews Flash: Analysts Just Made A Sizeable Upgrade To Their Clearfield, Inc. (NASDAQ:CLFD) Forecasts - Nasdaq
nasdaq.com - April 29 at 1:37 PM
Should You Review Recent Insider Transactions At Match Group, Inc. (NASDAQ:MTCH)? - NasdaqShould You Review Recent Insider Transactions At Match Group, Inc. (NASDAQ:MTCH)? - Nasdaq
nasdaq.com - April 28 at 9:46 AM
What You Need To Know About Misonix, Inc.s (NASDAQ:MSON) Investor Composition - NasdaqWhat You Need To Know About Misonix, Inc.'s (NASDAQ:MSON) Investor Composition - Nasdaq
nasdaq.com - April 27 at 6:50 PM
What Kind Of Shareholders Hold The Majority In Metacrine, Inc.s (NASDAQ:MTCR) Shares? - NasdaqWhat Kind Of Shareholders Hold The Majority In Metacrine, Inc.'s (NASDAQ:MTCR) Shares? - Nasdaq
nasdaq.com - April 27 at 1:49 PM
 Analysts Expect Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per Share Analysts Expect Metacrine, Inc. (NASDAQ:MTCR) Will Announce Earnings of -$0.52 Per Share
americanbankingnews.com - April 18 at 4:58 PM
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roches Asthma Drug - BenzingaThe Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug - Benzinga
benzinga.com - April 13 at 9:03 AM
Appointments and advancements for April 6, 2021 | 2021-04-06 - BioWorld OnlineAppointments and advancements for April 6, 2021 | 2021-04-06 - BioWorld Online
bioworld.com - April 6 at 10:52 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors - GlobeNewswireMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors - GlobeNewswire
globenewswire.com - April 6 at 12:35 AM
Metacrine (MTCR) Appoints Dr. Julia C. Owens to Its Board of Directors - StreetInsider.comMetacrine (MTCR) Appoints Dr. Julia C. Owens to Its Board of Directors - StreetInsider.com
streetinsider.com - April 5 at 7:34 PM
METACRINE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.comMETACRINE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - April 5 at 7:34 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors - BioSpaceMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors - BioSpace
biospace.com - April 5 at 7:34 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of DirectorsMetacrine Appoints Dr. Julia C. Owens to Its Board of Directors
finance.yahoo.com - April 5 at 7:34 PM
RBC Capital Keeps Their Buy Rating on Metacrine (MTCR) - Analyst RatingsRBC Capital Keeps Their Buy Rating on Metacrine (MTCR) - Analyst Ratings
analystratings.com - March 21 at 10:20 PM
Form 8-K Metacrine, Inc. For: Mar 16 - StreetInsider.comForm 8-K Metacrine, Inc. For: Mar 16 - StreetInsider.com
streetinsider.com - March 19 at 12:45 AM
METACRINE, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.comMETACRINE, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - March 18 at 7:44 AM
Metacrine Inc to Host Earnings Call - Yahoo FinanceMetacrine Inc to Host Earnings Call - Yahoo Finance
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswireMetacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire
globenewswire.com - March 18 at 7:44 AM
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsMetacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Inc to Host Earnings CallMetacrine Inc to Host Earnings Call
finance.yahoo.com - March 18 at 7:44 AM
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Yahoo FinanceMetacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - Yahoo Finance
finance.yahoo.com - March 12 at 11:57 PM
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ...
apnews.com - March 12 at 6:56 PM
DateCompanyBrokerageAction
3/22/2021SavaraOppenheimerInitiated Coverage
3/22/2021SavaraPiper SandlerInitiated Coverage
12/15/2020SavaraHC WainwrightLower Price Target
11/23/2020SavaraEvercore ISIInitiated Coverage
10/3/2019SavaraLADENBURG THALM/SH SHReiterated Rating
6/13/2019SavaraCanaccord GenuityLower Price Target
6/13/2019SavaraJMP SecuritiesDowngrade
5/14/2019SavaraRoth CapitalSet Price Target
9/11/2020Minerva NeurosciencesWilliam BlairReiterated Rating
6/1/2020Minerva NeurosciencesBTIG ResearchLower Price Target
5/29/2020Minerva NeurosciencesJefferies Financial GroupDowngrade
12/2/2019Minerva NeurosciencesChardan CapitalReiterated Rating
8/3/2018Minerva NeurosciencesCitigroupBoost Price Target
1/22/2021Adamis PharmaceuticalsMaxim GroupReiterated Rating
8/24/2020Adamis PharmaceuticalsDawson JamesDowngrade
8/19/2020Adamis PharmaceuticalsRaymond JamesReiterated Rating
7/23/2019Adamis PharmaceuticalsB. RileyUpgrade
2/10/2021Corvus PharmaceuticalsMizuhoDowngrade
3/13/2020Corvus PharmaceuticalsWedbushLower Price Target
11/2/2018Corvus PharmaceuticalsCowenReiterated Rating
8/15/2018Corvus PharmaceuticalsCredit Suisse GroupUpgrade
3/21/2021MetacrineRoyal Bank of CanadaReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.